Piper Jaffray analyst William Quirk says he found 41 NovaSeq installs during Q2, just above his 40 estimate but below the Street's 50 system target. The checks suggest limited NovaSeq placement upside in the quarter, Quirk tells investors in a research note. While a NovaSeq placement miss may move the stock lower, any shortfall could be made up with HiSeq X consumables and the array business, the analyst adds. He believes Illumina can meet revenue expectations for Q2. Quirk recommends using any earnings-related selloff in Illumina shares as a buying opportunity and keeps an Overweight rating on the name with a $200 price target.